Composition for Anti-inflammation and moisture enhancment of skin, comprising extract of filipendula palmata (pall.) maxim. as active ingredient

The maple leaf extract composition addresses the challenges of inflammatory skin diseases by inhibiting inflammatory pathways and enhancing skin hydration, offering a promising treatment for ISD through its anti-inflammatory and moisturizing effects.

WO2024242226A1PCT designated stage expired Publication Date: 2024-11-28CHUNG ANG UNIV IND ACADEMIC COOP FOUND
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/008681
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2023-06-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Inflammatory skin diseases (ISD) are exacerbated by damaged skin barriers, leading to increased transepidermal water loss and dehydration, and current treatments lack effective anti-inflammatory and moisturizing solutions that address the underlying immune system dysregulation and chemokine overproduction.

Method used

A composition containing maple leaf extract, preferably a 50-70% ethanol extract of Filipendula palmata, which inhibits MAPK and NF-κB signaling pathways, thereby reducing inflammatory chemokine production and enhancing skin moisturization by upregulating hyaluronic acid production through the regulation of HYAL and HAS enzymes.

Benefits of technology

The maple leaf extract composition effectively reduces inflammation and improves skin hydration by inhibiting inflammatory pathways and increasing hyaluronic acid production, as demonstrated in keratinocyte models, providing a potential treatment for inflammatory skin diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023008681_28112024_PF_FP_ABST
    Figure KR2023008681_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for anti-inflammation and moisture enhancement of the skin, and, specifically, provides: a composition comprising an extract of Filipendula palmata (Pall.) Maxim. as an active ingredient so as to exhibit the effects of skin inflammation inhibition and moisture enhancement; and a pharmaceutical composition, a health functional food composition and a cosmetic composition, which comprise same.
Need to check novelty before this filing date? Find Prior Art

Description

A composition for skin anti-inflammation and moisturizing effect containing maple leaf extract as an active ingredient

[0001] The present invention relates to a composition for skin anti-inflammation and moisturizing enhancement, comprising an extract of maple syrup as an active ingredient.

[0002] Inflammation is closely related to various diseases caused by infection or tissue damage, especially in the skin. Destruction of the epidermal barrier and immune system dysfunction are major causes of inflammatory skin disease (ISD). A damaged skin barrier allows various allergens to easily access the skin, leading to immune system dysregulation and the development and exacerbation of ISD. Overexpressed chemokines, acting as proinflammatory mediators, are a key factor in the progression of ISD.

[0003] According to current knowledge, inflammatory chemokines are primarily produced by leukocytes and infiltrating cells, such as keratinocytes, Langerhans cells, and neutrophils. Various environmental stimuli, including those resulting from epidermal barrier damage, promote the secretion of inflammatory chemokines by keratinocytes, stimulation of dendritic cells and Langerhans cells, and activation of type 2 helper T cells (Th2), which in turn produce Th2-type cytokines. This leads to barrier dysfunction, impaired keratinocyte differentiation, and persistent pruritus. Furthermore, impaired stratum corneum permeability induces dehydration due to increased transepidermal water loss and exacerbates inflammation through increased release of inflammatory cytokines, particularly chemokines. In vitro keratinocyte models are used to investigate the potential use of various natural and synthetic substances as anti-inflammatory candidates, as they interact with other cells and play a pivotal role in the progression and pathogenesis of ISD.

[0004] Meadowsweets (genus Filipendula), belonging to the Rosaceae family, are perennial herbaceous plants that prefer moist habitats such as wet meadows. They have been traditionally used in folk medicine for their therapeutic properties, including diuretic, antiseptic, antirheumatic, astringent, gastrointestinal, and antacid properties.

[0005] Although the genus Filipendula includes about 30 species, most research has focused on two major species: F. ulmaria (L.) Maxim (meadowsweet) and F. vulgaris Moench (dropwort). Meanwhile, F. palmata (Pall.) Maxim, also known as Siberian meadowsweet, is distributed primarily in North Korea, northeastern China, and eastern Russia. Therefore, the present inventors extracted and analyzed bioactive compounds from F. ulmaria to elucidate its anti-inflammatory and moisturizing effects on the skin.

[0006] The purpose of the present invention is to provide a composition for skin anti-inflammation and moisturizing enhancement, which contains an extract of maple syrup as an active ingredient.

[0007] Other objects and advantages of the present invention will become more apparent from the detailed description, claims and drawings below.

[0008] The present invention provides a composition for skin anti-inflammation and moisturizing enhancement, comprising an extract of maple syrup as an active ingredient.

[0009] In the present invention, the extract of the Korean maple tree refers to an extract obtained by extracting the leaves, stems, aerial parts, rhizomes, roots, underground parts, or mixtures thereof of the Korean maple tree using water, lower alcohols having C1 to C4 content, or a mixed solvent thereof. Preferably, the extract may be obtained by extracting water, methanol, ethanol, ethyl acetate, acetone, hexane, dichloromethane, or a mixed solvent thereof.

[0010] In the present invention, it is preferable that the maple leaf extract is a 50 to 70% ethanol extract.

[0011] In the present invention, conventional methods in the art such as filtration, hot water extraction, immersion extraction, room temperature extraction, accelerated solvent extraction, reflux cooling extraction, and ultrasonic extraction can be used as extraction methods for extracting the maple leaf extract.

[0012] In the present invention, the Filipendula palmata extract (FPE) may include a flavonoid compound. The flavonoid compound may include at least one selected from the group consisting of (+)-catechin, gambiriin C, miquelianin, scutellarin, and quercitrin. Preferably, the flavonoid compound included in the Filipendula palmata extract of the present invention may include miquilianin and quercitrin.

[0013] According to one embodiment of the present invention, the extract of the Korean maple tree has an activity of inhibiting MAPK and NF-κB, making it effective for anti-inflammation. The extract of the Korean maple tree has an activity of increasing HA production through downregulation of HYAL (HYAL1 and HYAL2) and upregulation of HAS (HAS1, HAS2, and HAS3), making it effective for promoting skin hydration.

[0014] In the present invention, the active ingredient means a component that exhibits the desired activity alone or can exhibit the activity together with a carrier that is inactive in itself.

[0015] In another embodiment of the present invention, the composition may be a pharmaceutical composition.

[0016] The characteristics corresponding to the above-described maple leaf extract included in the above pharmaceutical composition can be replaced in the above-described part, and therefore, their description is omitted.

[0017] When the composition according to the present invention is in the form of a pharmaceutical composition, it may contain a pharmaceutically effective amount of a maple leaf extract alone or may contain one or more pharmaceutically acceptable carriers. At this time, the pharmaceutically acceptable carriers are those commonly used in formulations, and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the composition may further contain a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.

[0018] The pharmaceutical composition of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method, and the dosage varies depending on the condition and weight of the patient, the degree of the disease, the drug form, the route of administration, and the time of administration, but can be appropriately selected by a person skilled in the art.

[0019] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment. The effective dosage level may be determined based on factors including the type and severity of the disease, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take all of the above factors into consideration and administer an amount that achieves the maximum effect with the minimum amount without causing side effects, and this can be easily determined by those skilled in the art.

[0020] Specifically, the effective dose of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, weight, absorption rate, inactivation rate and excretion rate of the active ingredient in the body, type of disease, and concomitantly administered drugs of the patient, and generally, 1 to 500 mg per 1 kg of body weight may be administered daily or every other day, or divided into 1 to 3 times a day. However, since the dosage may increase or decrease depending on the route of administration, sex, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.

[0021] In another embodiment of the present invention, the composition may be a health functional food composition.

[0022] Since the characteristics corresponding to the above-described maple leaf extract included in the above health functional food composition can be replaced in the above-described part, their description is omitted.

[0023] When the composition according to the present invention is in the form of a health functional food composition, it can be manufactured as a food with high medical and medical effects processed to efficiently exhibit a bioregulatory function in addition to a specific health food and nutritional supply, and the food can be mixed as a functional food, health food, or health supplement, depending on the case, and can be manufactured in various forms such as tablets, capsules, powder, granules, liquid, and pills to obtain useful effects.

[0024] The health functional food of the present invention may include additional ingredients commonly used in food compositions to improve odor, taste, sight, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), etc. In addition, it may include amino acids such as lysine, tryptophan, cysteine, and valine. In addition, food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder and high-purity bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), coloring agents (tar color, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, D-potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (pastes), film agents, gum bases, foam suppressants, solvents, and improvers can be added. The above additives can be selected depending on the type of food and used in an appropriate amount.

[0025] When the health functional food of the present invention is used as a food additive, it can be added as is or used together with other foods or food ingredients, and can be used appropriately according to a conventional method.

[0026] In the health functional food of the present invention, the content of the maple leaf extract is not particularly limited and may vary depending on the condition of the subject of administration, the type and extent of the specific disease, etc. If necessary, it may also be included as the total content of the food.

[0027] In another embodiment of the present invention, the composition may be a cosmetic composition.

[0028] Since the characteristics corresponding to the above-described maple leaf extract included in the above cosmetic composition can be replaced in the above-described part, their description is omitted.

[0029] If the composition according to the present invention is a cosmetic composition, it can be used externally on the skin or taken orally.

[0030] The cosmetic composition of the present invention contains an extract of the Korean maple tree as an active ingredient and can be manufactured in the form of a basic cosmetic composition (a face wash such as a toner, cream, essence, cleansing foam, and cleansing water, a pack, a body oil), a color cosmetic composition (foundation, lipstick, mascara, makeup base), a hair product composition (shampoo, rinse, hair conditioner, hair gel), and a soap, together with a dermatologically acceptable excipient.

[0031] The above excipients are not limited thereto, but may include, for example, skin softeners, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners, and solvents. In addition, fragrances, pigments, bactericides, antioxidants, preservatives, and moisturizers may be additionally included, and thickeners, inorganic salts, synthetic polymers, and the like may be included for the purpose of improving physical properties. For example, when preparing a cleanser and soap using the cosmetic composition of the present invention, the cleanser and soap can be easily prepared by adding the extract of the Korean maple tree to a conventional cleanser and soap base. When preparing a cream, the cleanser can be prepared by adding the extract of the Korean maple tree or its salt to a general oil-in-water (O / W) cream base. To this, synthetic or natural materials such as fragrances, chelating agents, pigments, antioxidants, preservatives, and proteins, minerals, and vitamins for the purpose of improving physical properties can be additionally added.

[0032] When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.

[0033] When the cosmetic composition of the present invention is in the form of a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether may be additionally included.

[0034] When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, a solubilizer or an emulsifier is used as a carrier component, and for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, fatty acid ester of sorbitan, etc. can be used.

[0035] When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester or polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, etc. can be used as a carrier component.

[0036] When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester may be used as a carrier component.

[0037] The composition for skin anti-inflammation and moisturizing enhancement, comprising the extract of the present invention as an active ingredient, exhibits activity for inhibiting MAPK and NF-κB signaling, thereby being effective for anti-inflammation. It also exhibits activity for increasing HA production through downregulation of HYAL and upregulation of HAS, thereby being effective for enhancing skin moisturizing.

[0038] Figure 1 shows the effect of FPE on the viability of normal HaCaT keratinocytes. Viability was assessed using (A) MTT and (B) live / dead cell staining methods. Live and dead cells were stained green and red, respectively. "ns" indicates no significant difference between all groups.

[0039] Figure 2 shows the effect of FPE on mitochondrial superoxide (Mito-SOX) production and intracellular reactive oxygen species (ROS) production in HaCaT keratinocytes induced by TNF-α + IFN-γ (10 ng / mL each) (T+I). Different superscripts indicate significant differences between groups as analyzed using Duncan's multiple range test (p < 0.05). DEX is dexamethasone (20 μg / mL).

[0040] Figure 3 shows the effect of FPE on (A) gene expression and (B) protein secretion of inflammatory chemokines in TNF-α + IFN-γ (10 ng / mL each) (T+I)-induced HaCaT keratinocytes. Results were obtained using qRT-PCR for mRNA expression and ELISA for protein secretion. Different superscripts indicate significant differences between groups, as analyzed using Duncan's multiple range test (p < 0.05). DEX is dexamethasone (20 μg / mL).

[0041] Figure 4 shows the effect of FPE on (A) MAPK and (B) NF-κB signaling pathways in HaCaT keratinocytes induced with TNF-α + IFN-γ (10 ng / mL each) (T+I). Results are presented as Western blot images of each protein and the quantified fold ratio of phosphorylated / total forms. Different superscripts indicate significant differences between groups as analyzed using Duncan's multiple range test (p < 0.05). DEX is dexamethasone (20 μg / mL).

[0042] Figure 5 shows the effect of FPE on (A) hyaluronic acid (HA) secretion and (B) HYAL and HAS gene expression in normal HaCaT keratinocytes. Results were obtained using ELISA for HA secretion and qRT-PCR for HA-related mRNA expression. Different superscripts indicate significant differences between groups, as analyzed using Duncan's multiple range test (p < 0.05). NAG is N-acetyl-D-glucosamine (5 mg / mL).

[0043] Figure 6 shows the effect of FPE on (A) HAS2 protein expression and (B) the PI3K / Akt / NF-κB signaling pathway in normal HaCaT keratinocytes. Results are presented as Western blot images of each protein and the quantified fold ratio of HAS2 / β-actin or phosphorylated / total forms. Different superscripts indicate significant differences between groups, as analyzed using Duncan's multiple range test (p < 0.05).

[0044] Figure 7 shows (A) the photodiode array chromatogram (PDA) and (B) the base peak chromatogram (BPC) results of FPE obtained by UPLC-MS analysis. The putative identities of five major phytochemicals in FPE are listed in the table below. FPE (10 mg / mL) was introduced into the UPLC-MS system, and the separation and detection conditions are described in Table 3.

[0045] Figure 8 shows (A) MS and (B) MS of the five major peaks identified in the base peak chromatogram (BPC, Figure 1B). 2 The spectrum is shown. Each peak in the spectrum is represented by a natural product database available online and an in-house MS 2 Identified using a spectral library.

[0046] Figure 9 shows the effects of major flavonoids on the viability and secretion of TARC and hyaluronic acid. (A) Viability and (B) TARC secretion were evaluated in TNF-α + IFN-γ (10 ng / mL each) (T+I)-induced HaCaT cells, and (C) viability and hyaluronic acid secretion were evaluated in normal HaCaT cells. Results were obtained using MTT (A and C) and ELISA (B and D) methods. Different superscripts indicate significant differences between groups analyzed using Duncan's multiple range test (p < 0.05). "ns" indicates no significant difference between all groups.

[0047] Figure 10 shows the content analysis of the active substance of FPE.

[0048] Hereinafter, to aid understanding of the present invention, examples will be given in detail. However, the following examples are intended only to illustrate the scope of the present invention and are not intended to limit its scope. These examples are provided to more fully explain the present invention to those of average skill in the art.

[0049]

[0050] Example 1. Materials and Methods

[0051]

[0052] 1.1. Materials and Methods

[0053]

[0054] Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS; F0900-050), West-Q Pico ECL solution (W3652), and AmfiSure qGreen Q-PCR master mix (Q5600-010) were purchased from GenDEPOT (Katy, TX, USA). Antibiotic-Antimycotic solution (100X) (P / S; CA002-010), TRIzol reagent (BIO-38033), and Superscript TMThe First-Strand cDNA Synthesis Kit (R5600-100) was purchased from Invitrogen Corp. (Carlsbad, CA, USA). Aqueous 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; M6494), dimethyl sulfoxide (DMSO; D2650-100ML), dexamethasone (D4902), N-acetyl-D-glucosamine (NAG; A3286), and Griess reagent (G4410) were purchased from Sigma-Aldrich (St. Louis, MO, USA). (+)-catechin (CAS No. 154-23-4), scutellarein 7-O-β-D-glucuronide (scutellarin; CAS No. 27740-01-8), quercetin 3-O-β-D-glucuronide (miquelianin; CAS No. 22688-79-5), and quercetin 3-O-α-L-glucuronide (quercitrin; CAS No. 522-12-3), used as standards, were provided by the Natural Product Institute of Science and Technology, Anseong, South Korea.

[0055] The live and dead cell viability / cytotoxicity assay kit (L3224) was purchased from Life Technologies Co. (Eugene, OR, USA). The ROS / superoxide detection assay kit (ab139476) was purchased from Abcam (Cambridge, UK). Recombinant human proteins corresponding to tumor necrosis factor-alpha (TNF-α; 210-TA-005) and interferon-gamma (IFN-γ; 285-IF-100) were purchased from R&D Systems (Minneapolis, MN, USA). Enzyme-linked immunosorbent assay (ELISA) kits for human interleukin-8 (IL-8 / CXCL8; 555244), thymus and activation regulatory chemokine (TARC / CCL17; DY364), and hyaluronan (HA; DHYAL0) were provided by BD Biosciences (Minneapolis, MN, USA) or R&D Systems (Minneapolis, MN, USA).

[0056] RIPA lysis buffer (89900) and bicinchoninic acid (BCA; 23225) protein assay kit were purchased from Thermo Fisher Scientific (Waltham, MA, USA). All primers for quantitative real-time PCR (qRT-PCR) were designed and provided by Macrogen (Seoul, South Korea), and their sequences are listed in Table 1. Primary antibodies for Western blotting were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA), and their Cat. No. are listed in Table 2.

[0057]

[0058] Primer Name ForwardReverseSequence (5'→3') IL-8 ForwardReverse 5'-GAGAGTGATTGAGAGTGGACCAC-3' (SEQ ID NO: 1) 5'-CACAACCCTCTGCACCCAGTTT-3' (SEQ ID NO: 2) TARC ForwardReverse 5'-TGTAAAACGACGGCCAGT-3' (SEQ ID NO: 3) 5'-CAGGAAACAGCTATGACC-3' (SEQ ID NO: 4) RANTES ForwardReverse 5'-CATATTCCTCGGACACCACACCCT-3' (SEQ ID NO: 5) 5'-ACTCCTGACCTCAAGTGATCCACC-3' (SEQ ID NO: 6) CTACK ForwardReverse 5'-CACTGCCTGCTGTACTCAGCTCTA-3' (SEQ ID NO: 7) 5'-CTTCAGCCCATTTTCCTTAGCATC-3' (SEQ ID NO: 8)HAS1ForwardReverse5'-CCTCACCAACCGCATGCT-3'(SEQ ID NO: 9)5'-GGACGAGGGCGTCTCTGA-3'(SEQ ID NO: 10)HAS2ForwardReverse5'-CTGGGACGAAGTGTGGATTATG-3'(SEQ ID NO: 11)5'-GATGAGGCTGGGTCAAGCAT-3'(SEQ ID NO: 12)HAS3ForwardReverse5'-GCCCTCGGCGATTCG-3'(SEQ ID NO: 13)5'-TGGATCCAGCACAGTGTCAGA-3'(SEQ ID NO: 14)HYAL1ForwardReverse5'-CCTCACCAACCGCATGCT-3'(SEQ ID NO: 15)5'-TCCTTGATGGCCTGACATGA-3'(SEQ ID NO: 16)HYAL2ForwardReverse5'-GCACTCCCAGTCTACGTCTTCA-3'(SEQ ID NO: 17)5'-GCACTCTCGCCAATGGTAGAG-3'(SEQ ID NO: 18)GAPDHForwardReverse5'-ACCACAGTCCATGCCATCAC-3'(SEQ ID NO: 19)5'-CCACCACCCTGTTGCTGTAG-3'(SEQ ID NO: 20)

[0059]

[0060] 항체제품번호제조사PhosphoPlus® p38 MAPKDuet #8203Cell signaling (Danvers, MA, USA)PhosphoPlus® p44 / 42 MAPK (Erk1 / 2)Duet #8201Cell signaling (Danvers, MA, USA)PhosphoPlus® SAPK / JNKDuet #8206Cell signaling (Danvers, MA, USA)PhosphoPlus® IκBαDuet #8219Cell signaling (Danvers, MA, USA)PhosphoPlus® NF-κB p65 / RelADuet #8214Cell signaling (Danvers, MA, USA)Phospho-Akt#9271Cell signaling (Danvers, MA, USA)Akt#9272Cell signaling (Danvers, MA, USA)Phospho-PI3 kinase p85#4228Cell signaling (Danvers, MA, USA)PI3 kinase p85#4292Cell signaling (Danvers, MA, USA)β-Actin mouse mAb#3700Cell signaling (Danvers, MA, USA)Anti-mouse IgG, HRP-linked#7076Cell signaling (Danvers, MA, USA)Anti-rabbit IgG, HRP-linked#7074Cell signaling (Danvers, MA, USA.)

[0061]

[0062] 1.2. 단풍터리풀 추출물(Filipendula palmata extract; FPE) 제조

[0063]

[0064] The whole plant of wild F. palmata was obtained from the northern part of Gyeonggi Province, adjacent to the DMZ in South Korea. The collected whole tissue (100 g) was dried under sunlight to obtain a dry matter (43.5 g). All dried tissues were extracted with 70% ethanol (5 L) at 20-25°C for 3 days. After filtration using a filter cloth (20 μm; Hyundai Micro, Anseong, South Korea), the extract was concentrated in a vacuum concentrator (Buchi Korea Inc., Gwangmyeong, South Korea) and dried using a freeze-dryer (Ilshin Biobase, Daejeon, South Korea). The 70% ethanol extract (FPE) powder of F. palmata was obtained (extraction yield, 11.5 w / w% compared to the raw material before drying).

[0065]

[0066] 1.3. Cell culture method for evaluating moisturizing capacity

[0067]

[0068] HaCaT cells were purchased from CLS Cell Line Service (Eppelheim, Heidelberg, Germany) and grown in DMEM containing 10% FBS and 1% P / S, regulated at 5% CO2 / 95% air. Cells were seeded in 6-well culture plates (for qRT-PCR and ELISA) and 5X10 5 2 x 10 in a 60mm dish (for Western blotting) 5Cells were plated at a density of 10 cells / well. The cells were allowed to stabilize for 24 hours, and the culture medium was replaced with fresh DMEM containing 1% P / S and various concentrations of FPE. Instead of FPE treatment, distilled water and N-acetyl-D-glucosamine (5 mg / mL) were applied to the cells as negative and positive controls, respectively. After culturing for 24 hours, hyaluronic acid (HA) secretion, nuclear mRNA expression, and intracellular signaling molecule expression in the culture supernatant were determined using ELISA (Example 1.5), qRT-PCR (Example 1.6), and Western blotting (Example 1.7), respectively.

[0069]

[0070] 1.4. Cell culture method for anti-inflammatory evaluation

[0071]

[0072] Anti-inflammatory activity was evaluated using TNF-α and IFN-γ (T+I)-induced HACAT cells. Briefly, HACAT cells were cultured at 2 х 10 in 96-well culture plates (MTT method) and 6-well culture plates (QRT-PCR and ELISA). 5 cells / well and 5 Х 10 5 2 Х 10 cells / 60 mm dish (Western blotting) 4 Cells were plated at a density of 10 cells / well. The cells were allowed to stabilize for 24 h, and the culture medium was replaced with fresh DMEM containing 1% P / S and various concentrations of FPE. Instead of FPE treatment, distilled water and dexamethasone (20 μg / mL) were applied to the cells as negative and positive controls, respectively.

[0073] After incubation for 1 h, a recombinant protein mixture containing 10 ng / mL TNF-α and 10 ng / mL IFN-γ (T+I) was added and further incubated for 24 h. After rinsing twice with PBS, cell viability was assessed by the MTT method at 570 nm using a microplate reader (Molecular Devices Filter Max F5; San Francisco, USA) according to a previously described method. In addition, after T+I treatment for 24 h, extracellular chemokine secretion, nuclear mRNA expression, and intracellular signaling molecule expression levels were evaluated in the culture supernatant using ELISA (Example 1.5), qRT-PCR (Example 1.6), and Western blotting (Example 1.7).

[0074]

[0075] 1.5. ELISA (enzyme-linked immunosorbent assay)

[0076]

[0077] After culturing FPE-treated HACAT cells for 24 h with or without T+I (Examples 1.3 and 1.4), culture supernatants were collected. Levels of extracellular chemokines and HA were determined using the respective ELISA kits according to the manufacturer's instructions.

[0078]

[0079] 1.6. qRT-PCR

[0080]

[0081] After incubating FPE-treated HACAT cells with T+I for 24 h or 24 h (Examples 1.3 and 1.4), the cells were rinsed twice with PBS. Total RNA was extracted with Trizol reagent and normalized using a nanodrop plate and microplate spectrophotometer (Epoch, Biotek Instruments, Winooski, VT, USA). Equal amounts of total RNA were then analyzed using SuperScript TM Reverse transcription was performed using the first-strand cDNA synthesis kit, and qRT-PCR was performed using AmfiSure qGreen Q-PCR Master Mix and qRT-PCR detection system (CFX96; Bio-Rad Laboratories, Hercules, CA, USA) with SYBR Premix Ex TaqTM II (TaKaRa Bio Inc., Kusatsu, Japan). Gene expression was normalized to that of the endogenous control gene (glyceraldehyde-3-phosphate dehydrogenase; GAPDH) and calculated using the 2-△△CT formula.

[0082]

[0083] 1.7. Western Blotting

[0084]

[0085] After culturing FPE-treated HaCaT cells with or without T+I for 24 h (Examples 1.3 and 1.4), the cells were rinsed twice with PBS. Total protein was extracted with RIPA lysis buffer and normalized using a BCA protein assay kit. Equal amounts (50 μg) of total protein were separated on a 10–12% sodium dodecyl sulfate-polyacrylamide gel, and the separated proteins were transferred from the gel to a polyvinylidene fluoride membrane (Thermo Fisher Scientific). The membrane was blocked with 5% skim milk and 0.05% Tween in PBS at 20–25°C for 2 h and washed three times with PBS containing 0.05% Tween 20 alone (PBST). The membrane was then incubated with primary antibodies overnight at 4°C. After washing three times with PBST, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody at 20–25 °C for 1 h. The membrane was then rinsed five times with PBST, and the target protein blots were visualized using ECL solution. The expression levels of each target protein were quantified using ImageJ software available online (https: / / imagej.nih.gov / ij / ).

[0086]

[0087] 1.8. Dyeing method

[0088]

[0089] HaCaT cells were seeded at 2 x 10 in 6-well culture plates. 5Cells were plated at a density of 10 cells / well and allowed to stabilize for 24 h. The culture medium was replaced with fresh DMEM containing 1% P / S and various concentrations of FPE. After incubation for 1 h, T+I was added and incubated for an additional 24 h. After washing twice with PBS, two staining methods were employed to evaluate cytotoxic effects and intracellular ROS and mitochondrial superoxide (Mito-SOX) production: live / dead cell staining and ROS / superoxide staining. All staining methods were used according to the manufacturer's instructions. Stained cells were visualized with a fluorescence scanning microscope (Leica, Wetzlar, Germany) and quantified using ImageJ software.

[0090]

[0091] 1.9. Identification of the main active ingredients of FPE

[0092]

[0093] Major secondary metabolites present in FPE were analyzed by chromatography and spectrometry using an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS; LTQ Orbitrap XL) manufactured by Thermo Electron (Waltham, MA, USA), referring to the previously described analytical methods and conditions (Kim et al., 2021). Details are provided in Table 3.

[0094]

[0095] Stationary phase: Acquity UPLC BEH C18 column (2.1 Х 150 mm, 1.7 μm)Mobile phase: 0.1% formic acid / water0.1% formic acid / acetonitrile0 min → 0.5 min (5% B), 0.5 min → 10 min (5% B → 80% B) → 10 min → 10.1 min (80% B → 100% B), 10.1 min → 12 min (100% B)Equilibration time: 3 minInjection volume: 400 μLIonization source and conditions: heated electrospray ionization (HESI), preheating at 300°C, spray voltage at 5.0 kVDetector: MS / MS at 100-1000 m / zData calculation: Xcalibur program (Termo Electrom Co.)

[0096]

[0097] 1.10. Statistical Analysis

[0098]

[0099] All experiments were performed in triplicate, and results are expressed as the mean ± standard deviation. Statistical analyses were performed using IBM SPSS Statistics (Ver. 26; IBM Co., Armonk, NY, USA). Statistical differences were assessed using one-way analysis of variance (ANOVA), and post hoc analyses were performed using Duncan's multiple range test. A p value less than 0.05 was considered statistically significant.

[0100]

[0101] Example 2. Experimental Results

[0102]

[0103] 2.1. Cytotoxicity and ROS inhibition effects of FPE

[0104]

[0105] The cytotoxic effect of FPE on HaCaT cells was evaluated using MTT and live / dead cell staining methods. As shown in Figure 1A, MTT results showed that no significant toxic effect was observed in FPE-treated cells at concentrations of 10–200 μg / mL.

[0106] To further confirm the cytotoxicity of FPE treatment, a live / dead staining assay was performed. Representative images are shown in Figure 1B, with green and red fluorescence images representing live and dead cells, respectively. The live / dead cell staining results are consistent with those observed in the MTT assay.

[0107] Next, to investigate whether FPE prevents T+I-induced oxidative stress in HaCaT cells, a ROS / superoxide assay was performed using fluorescence microscopy (Fig. 2). The results showed two specific fluorescent probes for detecting Mito-SOX (red) and intracellular ROS (green). The levels of Mito-SOX and ROS were significantly increased by T+I treatment compared to those in the negative control (NC) group treated with medium alone.

[0108] This phenomenon was significantly improved by pretreatment with dexamethasone, which served as a positive control (PC). Furthermore, FPE treatment effectively inhibited Mito-SOX and ROS formation in a concentration-dependent manner. In particular, treatment with the highest FPE concentration (100 μg / mL) showed a decrease in both Mito-SOX and ROS production compared to the PC group.

[0109]

[0110] 2.2. Inhibitory effect of FPE on TNF-α / IFN-γ-induced inflammatory chemokines

[0111]

[0112] The effects of FPE on the production of key proinflammatory chemokines, such as RANTES, TARC, CTACK, and IL-8, were evaluated in T+I-induced HaCaT cells. As shown in Figure 3A, qRT-PCR results showed that T+I stimulation significantly increased the mRNA expression of the aforementioned proinflammatory chemokines compared to the NC group.

[0113] In contrast, the PC group treated with dexamethasone showed a significant decrease in the expression of these inflammatory chemokines compared to the T+I-induced group. FPE pretreatment significantly reduced the expression of all measured chemokines. In particular, treatment with the highest FPE concentration (100 μg / mL) showed a decrease in the expression of all chemokines compared to the PC group. Next, the secretion levels of IL-8 and TARC in T+I-stimulated HaCaT cells were measured using an ELISA method (Fig. 3B).

[0114] Consistent with the qRT-PCR results, IL-8 and TARC were over-secreted from cells after T+I stimulation, but their secretion was significantly inhibited in a concentration-dependent manner by FPE pretreatment. Overall, the qRT-PCR and ELISA results demonstrate that FPE treatment effectively modulates T+I-stimulated production of inflammatory chemokines at the gene and protein levels.

[0115]

[0116] 2.3. FPE-mediated inhibition of MAPK and NF-κB signaling in T+I-stimulated inflammatory responses

[0117]

[0118] To elucidate the molecular mechanisms associated with the anti-inflammatory effects of FPE, the effects of T+I treatment and FPE pretreatment on mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways, which are important in the regulation of proinflammatory mediators, were evaluated.

[0119] Figure 4 provides immunoblotting images and quantified results using image processing software. After T+I treatment, the phosphorylation levels of three MAPKs, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 kinase (p38), were significantly increased without increasing the total levels (Figure 4A).

[0120] Additionally, the expression levels of intact NF-κB p65 (p65) and phosphorylated form (p-p65) in T+I-stimulated cells showed a similar trend to that observed in the three MAPKs mentioned above (Fig. 4B).

[0121] T+I stimulation significantly increased the phosphorylation level of IκBα, while conversely decreasing its total level. These significant changes in three MAPKs and two NF-κB molecules induced by T+I stimulation were significantly reversed by FPE pretreatment in a concentration-dependent manner.

[0122]

[0123] 2.4. Effect of FPE on HA production and related gene expression

[0124]

[0125] The skin moisturizing effect of FPE was investigated using normal HaCaT cells. HA secretion levels in FPE-treated HaCaT cell supernatants were determined using ELISA, as shown in Figure 5A.

[0126] To compare the efficacy of FPE, cells were treated with NAG (5 mg / mL) and used as the PC group. The results indicated that FPE treatment significantly increased HA secretion in a concentration-dependent manner. In particular, FPE treatment at a concentration of 100 μg / mL induced HA secretion 4.1 times more significantly than the NC group treated with medium alone.

[0127] Next, qRT-PCR was used to investigate the HA production mechanism, examining the expression of HA-related genes. After FPE treatment, the mRNA expression of two types of hyaluronidase (HYAL; HYAL1 and HYAL2) was significantly downregulated (Fig. 5B), whereas the mRNA expression of three types of hyaluronic acid synthase (HAS; HAS1, HAS2, and HAS3) was extensively upregulated in HaCaT cells (Fig. 5C). These results suggest that FPE can promote HA production by upregulating HA synthase (HAS) and downregulating HA degrading enzyme (HYAL).

[0128]

[0129] 2.5. FPE-mediated HAS2 synthesis and PI3K / Akt signaling stimulation in normal keratinocytes

[0130]

[0131] Based on the above results showing that FPE treatment promotes HA secretion, we further investigated whether FPE treatment activates the synthesis of HAS2, a key membrane-bound HA synthase in HAS. As shown in Figure 6A, HAS2 protein expression increased in a dose-dependent manner by FPE treatment.

[0132] Furthermore, the intracellular signaling pathway underlying FPE-mediated HA production was investigated using immunoblotting. Figure 6B provides blot images and quantification results of phosphoinositide 3-kinase (PI3K) / protein kinase B (PKB; Akt) and NF-κB signaling molecules. These results showed that FPE treatment significantly and dose-dependently improved the phosphorylated levels of PI3K, Akt, IκBα, and p65 proteins without altering their corresponding total proteins.

[0133] Taken together, the above results suggest that FPE-mediated HA production is associated with the activation of PI3K / Akt / NF-κB signaling and HAS2 synthesis.

[0134]

[0135] 2.6. Identification of the effective ingredients for the anti-inflammatory effect and hyaluronic acid production of FPE

[0136]

[0137] UPLC-MS / MS analysis was performed to determine the main active compounds that play a role in the inflammatory activity of FPE. Figures 7A and 7B provide the photodiode array chromatogram (PDA) and base peak chromatogram (BPC) of FPE, respectively. Mass spectrometry (MS) and tandem MS (MS) were performed on BPC. 2 ) was used to additionally measure the mass-to-charge ratio (m / z) and identify key peaks by searching the internal spectral library and web-based database with a mass accuracy of less than ±5 ppm.

[0138] Positive ionization mode ([M+H] +) MS analysis showed that five peaks at retention times 3.96, 4.63, 6.64, 7.38 and 7.50 min in BPC were identified as matching precursor ions at 291.0849, 563.1520, 479.0792 and 463.0848 and 449.1059 m / z, respectively (Fig. 8A). These precursor ions were identified as MS 2 was further analyzed using and generated product ions (daughter ions) as shown in Figure 8B.

[0139] As a result, MS and MS 2 The results suggest that FPE contains five major flavonoids, including (+)-catechin, gambiriin C (epiafzelechin-(4β->8)-catechin), miquelianin (quercetin 3-O-β-D-glucuronide), scutellarin (scutellarein 7-O-β-D-glucuronide), and quercitrin (quercetin 3-O-α-L-rhamnoside). Except for gambirin C, the putative identification of (+)-catechin, myquilianin, scutellarin and quecitrin was finally confirmed by MS and MS analysis between FPE and the above-mentioned reference substances. 2 This was confirmed by comparing the ion spectra obtained using .

[0140] Meanwhile, the effects of the major compounds and FPE on TARC inhibition and HA production were evaluated in T+I-induced and normal HaCaT cells, respectively, to investigate their contribution to the bioactivity of HaCaT cells. As shown in Figures 9A and 9B, the MTT results showed that the two major compounds (miquilianine and quecitrin) and FPE did not exert significant toxic effects at the same concentrations (40-100 μg / mL) in both T+I-stimulated and normal HaCaT cells. The highest inhibitory activity against T+I-induced TARC production was observed in cells treated with FPE, followed by miquilianine and quecitrin (Figure 9C). Conversely, HA secretion in normal HaCaT cells was maximal with quecitrin treatment, followed by miquilianine and FPE (Figure 9D).

[0141]

[0142] 2.7. Content analysis of active substances in FPE

[0143]

[0144] The contents of active substances myquilianine and quecitrin present in FPE were analyzed. For content analysis, a YMC Pack Pro C18 column (4.6 X 250 mm, 5 μm) was used as a stationary phase on an Agilent 1260 Infinity II Quat Pump (CA, USA) and an Agilent Variable Wavelength (VW) UV Detector (CA, USA). Each column used a mobile phase (A: 0.1% formic acid / water, B: acetonitrile) with an injection volume of 5 μL at 40°C and was processed at a flow rate of 0.9 mL / min. Detection was performed using an Agilent Variable Wavelength (VW) UV Detector (UV 270 nm). The mobile phase was eluted under the conditions of Table 4 below, and the following formula was used for calculation.

[0145]

[0146] Time (min)Movement phase AB09010157525306535355050400100450100509010609010

[0147]

[0148] Content of standard (mg / g) = C Х V Х D Х P / W

[0149] (C: concentration of standard in test solution (mg / mL); V: total volume of test solution (mL); D: dilution factor; P: purity of standard; W: sample amount (g))

[0150]

[0151] As a result, as shown in Fig. 10, it was confirmed that the active substances miquilianine and quecitrin present in FPE were contained in amounts of 4.72 ± 0.01 (mg / g) and 13.66 ± 0.01 (mg / g), respectively.

[0152]

[0153] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A composition for skin anti-inflammation and moisturizing, containing maple leaf extract as an active ingredient.

2. In paragraph 1, A composition for skin anti-inflammation and moisturizing enhancement, wherein the extract is extracted using water, methanol, ethanol, ethyl acetate, acetone, hexane, dichloromethane or a mixed solvent thereof.

3. In paragraph 1, A composition for skin anti-inflammation and moisturizing, wherein the extract is a 50 to 70% ethanol extract of maple syrup.

4. In paragraph 1, The above extract is a composition for skin anti-inflammatory and moisturizing effect, which contains a flavonoid series compound.

5. In paragraph 4, A composition for skin anti-inflammation and moisturizing enhancement, wherein the flavonoid series compound comprises at least one selected from the group consisting of (+)-catechin, gambirin C, myquilianin, scutellarin, and quecitrin.

6. In paragraph 1, A composition for skin anti-inflammation and moisturizing, wherein the above-mentioned maple leaf extract has the activity of inhibiting MAPK and NF-κB.

7. In paragraph 1, The above-mentioned maple leaf extract is a composition for skin anti-inflammatory and moisturizing that increases HA production through down-regulation of HYAL and up-regulation of HAS.

8. In any one of paragraphs 1 to 7, The above composition is a pharmaceutical composition for skin anti-inflammatory and moisturizing enhancement.

9. In any one of paragraphs 1 to 7, The above composition is a composition for skin anti-inflammation and moisturizing enhancement, which is a health functional food composition.

10. In any one of paragraphs 1 to 7, The above composition is a cosmetic composition for skin anti-inflammatory and moisturizing enhancement.

Citation Information

Patent Citations

  • Promoter for production of hyaluronic acid and preparation for external use for skin

    JP2001163794A

  • Cosmetic composition comprising the extract of filipendula formosa as active ingredient

    KR1020110122448A

  • Process apparatus for lancing steam generators of nuclear power plant

    KR102271668B1